10 results
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A
2017 ACC/AHA/HFSA ... 2013 ACCF/AHA Guideline ... American College of Cardiology ... #ACCAHA2017 #cardiology ... #treatment #algorithm
Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - ANCA Vasculitis Management Algorithm - ACR/VF 2021
Polyangiitis (MPA) - ANCA ... - ACR/VF 2021 Guidelines ... Polyangiitis #MPA #ANCA ... Vasculitis #Management #Treatment ... #ACR2021 #Guidelines
Eosinophilic Granulomatosis with Polyangiitis (EGPA) - ANCA Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Active
Polyangiitis (EGPA) - ANCA ... - ACR/VF 2021 Guidelines ... #Polyangiitis #ANCA ... Vasculitis #Management #Treatment ... #ACR2021 #Guidelines
Pharmacologic treatment algorithms by Global Initiative for Chronic Obstructive Lung Disease grade. Highlighted boxes and arrows
Pharmacologic treatment ... algorithms by Global ... indicate preferred treatment ... GOLD2017 #LAMA #LABA #ICS ... #Guidelines
Heart Failure (HFrEF) Treatment - GDMT for stage C 

For patients with Heart Failure with REDUCED
Failure (HFrEF) Treatment ... getting patients on medication ... /AHA guidelines. ... HeartFailure #HFrEF #Pharmacology ... #StageC #Cardiology
HFpEF and CAD Management Algorithm
1. Consider revascularization based on current guidelines for CAD and HFpEF*
2. Statins:
CAD Management Algorithm ... based on current guidelines ... indicated by current guidelines ... controlled by above medications ... #cardiology
Iron Deficiency in Heart Failure - Diagnosis and Treatment Algorithm
Diagnosis: Ferritin <100 ng/mL (absolute ID) OR
Diagnosis and Treatment ... Algorithm Diagnosis ... : • ACC/AHA 2017 ... #cardiology #treatment ... #guidelines
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
For most indications ... #management #algorithm ... #pharmacology # ... treatment #medications ... #decisionaid #cardiology
Daliresp (Roflumilast) 
Indication: Reduce risk of COPD exacerbations 
Drug Class: Selective Phosphodiesterase-4 (PDE4) Inhibitor 
GOLD 2019
Inhibitor GOLD 2019 Guideline ... 2019 COPD GOLD guidelines ... recommendations for the treatment ... the use of this medication ... #Pharmacology #
AACE/ACE 2016 Postmenopausal Osteoporosis Treatment Algorithm

Evaluate for causes of secondary osteoporosis

Correct calcium/vitamin D deficiency and address
AACE/ACE 2016 Postmenopausal ... Osteoporosis Treatment ... Algorithm Evaluate ... • Recommend pharmacologic ... benefits and risks of medications